Search PubMedSearch

Biomedical subjects

Emery H Bresnick

Publications and source records attributed to Emery H Bresnick.

2 recordsLinked to original sources

Systematic background selection with BasCoD enhances contrastive dimension reduction in single cell genomics.

In single-cell experiments spanning diverse conditions, distinguishing variation specific to one condition (e.g., treatment) from shared or background variation (e.g., control) is critical for uncovering treatment-specific molecular responses. However, these studies typically yield ultra-high-dimensional data, necessitating effective dimension reduction for reliable biological interpretation. Contrastive dimension reduction methods address this challenge by identifying low-dimensional features enriched in a target dataset relative to a background dataset that captures shared variation. Despite their growing utility, the success of such methods critically depends on the choice of background, yet no formal criterion exists for evaluating or selecting backgrounds. To address this gap, we introduce BasCoD, a statistical testing framework based on spectral subspace inclusion theory, that enables rigorous evaluation and systematic selection of background datasets. Applying BasCoD across a range of single-cell datasets, we show that it effectively identifies suitable backgrounds, substantially improving the contrast and interpretability of the resulting target representations. We further demonstrate how BasCoD can guide the design of contrastive analyses in large-scale single-cell experiments conducted under heterogeneous conditions and elucidate potential interaction effects in perturbation studies.

Single-Cell Analysis

Oncogenic DEAD-box ATPase DDX41 establishes transcript ensembles via CLK3-dependent and -independent mechanisms.

Post-transcriptional diversification of RNA transcripts mediated by complex processing machinery, including DEAD-box ATPases, establishes and maintains cellular phenotypes. For example, DDX41 controls RNA splicing, innate immune signaling, and genome stability. Although heterozygous DDX41 germline genetic variation occurs in familial myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), the DDX41 contributions to splicing globally, biological processes, and pathogenic mechanisms are incompletely defined. Using a genetic rescue system with Ddx41+/- myeloid progenitors, we established global wildtype DDX41 and pathogenic variant mechanisms. Differing from pathogenic variants of other RNA splicing regulators, DDX41 deficiency compromised multiple splicing steps. DDX41-regulated transcripts encoded factors controlling RNA splicing, including Cdc2-like kinase 3 (CLK3). DDX41 regulated Clk3 transcripts, and elevated CLK3 during myeloid differentiation. Loss-of-function analysis revealed DDX41-regulated splicing commonly, but not always, required CLK3. Thus, through a mechanism utilizing a splicing factor kinase that itself is DDX41-regulated, DDX41 establishes transcript ensembles in myeloid progenitors.

DEAD-box RNA Helicases